The U.S. Food and Drug Administration (FDA) approves the FlexPro PenMate designed by Danish pharmaceutical company Novo Nordisk for Norditropin patients who dislike needles.
New research shows that the drug Liraglutide 3.0 mg, produced by Danish pharmaceutical company Novo Nordisk, is highly effective in creating significant long-term weight loss, lowering blood pressure, and increasing insulin sensitivity among obesity patients.
A new report from Dansk Hjerteregister, a nationwide clinical database for invasive cardiology and cardiac surgery, shows that fewer Danish patients die due to heart problems.
An Ebola vaccine developed by Danish Bavarian Nordic reaches phase 2 in the clinical program.
The U.S. Food and Drug Administration, FDA, has approved a new drug by Danish pharmaceutical company H. Lundbeck A/S and Japanese Otsuka Pharmaceutical Co Ltd. The drug will help treat patients with severe depression and schizophrenia.
Danish researchers have exposed a protein, which can predict the development of asthma.
The growing market for individualized pharmacotherapy, also called personalized medicine, is worth billions on a global level. In Denmark, personalized medicine is considered to have great potential and provides an opportunity to launch a new innovative project offering genetic heritage analyses to 100,000 Danes.
Randers Regional Hospital introduces a new operation method with a 50 pct. higher success rate.
HRH Princess Marie of Denmark enters into collaboration with the Hans Christian Andersen Children’s Hospital at Odense University Hospital to help raise awareness of the hospital’s work with children and adolescents.
The Danish NEXT initiative has applied to establish two new pilot study centers following massive interest from both industry and hospitals.